Company:  NXSTAGE MEDICAL, INC. (NXTM)
Form Type:  10-Q
Filing Date:  5/2/2013 
CIK:  0001333170 
Address:  350 MERRIMACK STREET 
City, State, Zip:  LAWRENCE, Massachusetts 01843 
Telephone:  978-687-4700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$11.95  
Change: 
0.28 (2.40%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$733.86M
Description of Business
We are a medical device company that develops, manufactures and markets innovative products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Our primary product, the System One, was designed to satisfy an unmet clinical need for a system that can deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis clinics. Given its design, the System One is particularly well-suited for home hemodialysis and a range of dialysis therapies including more frequent dialysis, which clinical literature suggests provides patients better clinical outcomes and improved quality of life. The System One is cleared or approved for commercial sale in the U.S.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements (unaudited)
        BALANCE SHEET
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
          INCOME STATEMENT
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4.Controls and Procedures
    PART II - OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A),
  EXHIBIT 31.2
    CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A),
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO
BROKERAGE PARTNERS